查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2014374

冠狀動脈疾病治療器材市場：依器材類型、治療類型、方法和最終用戶分類－2026-2032年全球市場預測

Coronary Artery Disease Treatment Devices Market by Device Type, Treatment Type, Approach, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025年冠狀動脈疾病治療設備的市值為48.4億美元，預計到2026年將成長至51.3億美元，複合年成長率為5.94%，到2032年將達到72.6億美元。

主要市場統計數據
基準年 2025 48.4億美元
預計年份：2026年 51.3億美元
預測年份 2032 72.6億美元
複合年成長率 (%) 5.94%

權威概述了正在重塑冠狀動脈疾病治療方法的臨床複雜性、醫療設備創新路徑和醫療保健重點。

技術創新、不斷變化的診療流程以及醫療服務模式的轉型，正推動冠狀動脈疾病治療器材的臨床和商業性格局快速發展。患者的病情日益複雜，包括嚴重鈣化、慢性完全阻塞、需要精細治療的合併症。同時，臨床醫生正將高解析度血管內影像和生理學工具融入日常決策中，以提高手術精準度和改善長期療效。

影像學、生理評估、斑塊改良和手術方法的發展趨勢如何匯聚，從而重新定義冠狀動脈治療的治療基準和器械應用？

多項變革正在重塑冠狀動脈介入治療的概念、設計和實施，加速影像學、生理評估和治療器械功能的整合。首先，血管內影像學和生理評估正從可有可無的輔助手段轉變為病例規劃和最佳化的核心組成部分。血管內超音波和光學同調斷層掃描（OCT）的廣泛應用，以及基於血流儲備分數（FFR）的決策，提高了病灶部​​位的診斷準確性，從而能夠更精準地選擇和部署器械。

評估美國關稅調整對冠狀動脈器械供應鏈和定價策略的累積營運、採購和監管影響。

2025年美國實施的關稅和貿易政策變化對醫療設備的採購、定價策略和供應鏈結構產生了累積影響，促使產業相關人員重新評估其商業模式。在受影響的地區，嚴重依賴零件和成品供應的製造商面臨利潤率壓力，加速了供應商多元化和近岸外包替代方案的探索。這些調整強調雙重採購策略、認證替代供應商以及最佳化庫存，以維持臨床供應的連續性。

將醫療設備模式、治療途徑、進入策略和醫療保健環境與採用促進因素和產品定位連結起來的深入細分分析。

精確的細分觀點揭示了每種醫療設備、治療方式、手術方法和終端用戶環境的明確機會領域和操作考量。在按類型對醫療設備進行分類時，分析應考慮動脈粥狀硬化斑塊切除術系統，包括雷射、軌道和旋轉等各種類型，每種系統都針對不同的斑塊形態和臨床場景進行了最佳化。球囊導管技術包括切割型、藥物塗層型和標準型，其中藥物塗層球囊在支架內血管再阻塞和微血管疾病中的重要性日益凸顯。導管導引線的種類繁多，例如聚合物包覆型、聚四氟乙烯（PTFE）塗層型和未處理型，根據病變的複雜程度和輸送要求，在手術中發揮不同的作用。血管內影像系統包括血流儲備分數（FFR）平台、血管內超音波（IVUS）和光學同調斷層掃描（OCT），每種系統都提供獨特的診斷解析度，有助於選擇合適的器械和製定手術方案。支架平台包括裸金屬支架、生物可吸收支架和藥物釋放型支架，急性支架作用、長期血管癒合和器械耐久性的權衡會影響臨床醫師的偏好。

影響監管路徑、實施重點和區域商業化策略的美洲、歐洲、中東和非洲以及亞太地區的區域趨勢。

美洲、歐洲、中東、非洲和亞太地區的區域趨勢造就了不同的需求促進因素和業務挑戰，並影響監管路徑、報銷環境和臨床實踐模式。在美洲，手術創新與整合的支付系統和大規模醫院網路密切相關，這些系統和網路優先考慮真實世界的臨床結果和成本效益。市場對手術效率的顯著提升和再次手術率的降低有著強烈的需求。在此背景下，製造商積極投資於可靠的上市後證據和醫療專業人員教育項目，以將器械優勢轉化為可衡量的臨床和經濟價值。

產品整合、臨床證據、供應鏈韌性和商業化專業知識如何決定冠狀動脈器械製造商的競爭優勢。

冠狀動脈介入器材研發企業的競爭格局受多種因素共同影響，包括技術領先性、臨床證據的累積、生產規模以及產品上市策略的成熟度。主要企業優先建構整合治療器材和診斷平台的一體化產品組合，從而提供更全面的治療方案，支持更精準的患者選擇和治療最佳化。隨著醫療系統日益重視可驗證的長期療效和經濟價值，對臨床試驗、註冊研究和上市後監測的投入仍然是企業脫穎而出的關鍵因素。

領導企業面臨的實際策略挑戰：協調產品創新、供應鏈韌性和基於證據的商業化，以實現永續成長。

產業領導者應優先考慮以臨床意義顯著的差異化、監管前瞻性和供應鏈適應性為重點的產品組合策略，以實現永續價值。首先，他們應有選擇地投資於能夠解決鈣化、微血管疾病和血管再阻塞等高影響臨床問題的器械改進，同時確保設計變更能夠提高經橈動脈入路的輸送性能。協調一致的臨床項目能夠產生隨機試驗證據和真實世界臨床註冊數據，從而增強對臨床醫生和保險公司的價值提案，促進更廣泛的應用並與報銷機制保持一致。

採用嚴謹且多方面的調查方法，整合臨床證據、相關人員訪談、監管見解和供應鏈分析，以得出可靠的結論。

本分析整合了多方面研究途徑的洞見，旨在反映臨床實踐、法規環境和供應鏈的實際情況。該調查方法包括對同行評審的臨床文獻、手術註冊資料和醫療設備附加檔進行全面審查，以確定醫療設備的性能特徵和臨床應用模式。此外，還對介入性心臟病專家、醫院採購經理、監管專家和醫療設備推廣應用的促進因素、未滿足的需求和營運限制的實際觀點。

對臨床、營運和策略促進因素進行簡潔整合，以確定哪種設備策略能夠帶來永續的臨床和商業性價值。

冠狀動脈疾病治療器材的發展演變取決於技術的精湛程度、手術流程的進步以及評估其臨床和經濟價值的環境。血管內影像和生理學的進步使得在病變層面做出更精準的決策成為可能，而從先進的動脈粥狀硬化斑塊切除術系統到藥物輸送球囊和尖端支架平台等標靶治療器械，則能夠應對日益複雜的臨床表現。這些臨床因素與准入趨勢、支付方審查和供應鏈壓力等實際營運因素相互交織，共同創造出有利於整合解決方案和實證商業化策略的環境。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 冠狀動脈疾病治療器材市場：依器械類型分類

  • 動脈粥狀硬化斑塊切除術裝置
    • 雷射動脈動脈粥狀硬化斑塊切除術
    • 眼眶動脈粥狀動脈粥狀硬化斑塊切除術
    • 旋切動脈粥狀硬化斑塊切除術
  • 球囊導管
    • 切割球囊導管
    • 藥物塗層球囊導管
    • 標準球囊導管
  • 導管導引線
    • 聚合物外殼
    • 聚四氟乙烯塗層
    • 未加工
  • 血管內成像系統
    • 部分血流儲備
    • 血管內超音波
    • 光學同調斷層掃描
  • 支架
    • 裸金屬支架
    • 生物可吸收支架
    • 藥物釋放型支架

第9章：冠狀動脈疾病治療器材市場（依治療方法）

  • 冠狀動脈繞道手術手術
    • 非泵送
    • 在心肺體外迴圈下
  • 經皮冠狀動脈介入治療
    • 球囊血管成形術
    • 支架置入

第10章：冠狀動脈疾病治療器材市場（依治療方法分類）

  • 股動脈路徑
  • 橈動脈入路

第11章 冠狀動脈疾病治療器材市場：依最終用戶分類

  • 門診手術中心
  • 心臟中心
  • 醫院

第12章 冠狀動脈疾病治療器材市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：冠狀動脈疾病治療器材市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 冠狀動脈疾病治療器材市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國冠狀動脈疾病治療器材市場

第16章：中國冠狀動脈疾病治療器材市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • B. Braun Melsungen AG
  • Biotronik SE & Co. KG
  • Boston Scientific Corporation
  • Cardinal Health, Inc.
  • Cook Medical Inc.
  • Edwards Lifesciences Corporation
  • GE Healthcare（subsidiary of General Electric Company）
  • Johnson & Johnson
  • Koninklijke Philips NV
  • Lepu Medical Technology（Beijing）Co., Ltd.
  • Medtronic plc
  • Meril Life Sciences Pvt. Ltd.
  • Merit Medical Systems, Inc.
  • MicroPort Scientific Corporation
  • OrbusNeich Medical Company Limited
  • Shockwave Medical, Inc.
  • Terumo Corporation
  • WL Gore & Associates, Inc.
Product Code: MRR-4311CE1A33CA

The Coronary Artery Disease Treatment Devices Market was valued at USD 4.84 billion in 2025 and is projected to grow to USD 5.13 billion in 2026, with a CAGR of 5.94%, reaching USD 7.26 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.84 billion
Estimated Year [2026] USD 5.13 billion
Forecast Year [2032] USD 7.26 billion
CAGR (%) 5.94%

An authoritative overview of clinical complexities, device innovation pathways, and healthcare priorities reshaping coronary artery disease treatment approaches

The clinical and commercial landscape for coronary artery disease treatment devices is evolving rapidly under the combined influence of technological innovation, shifting procedural preferences, and changing healthcare delivery models. Patients present with increasingly complex anatomies including heavily calcified lesions, chronic total occlusions, and comorbidities that demand nuanced therapeutic approaches. At the same time, clinicians are integrating higher-resolution intravascular imaging and physiology tools into routine decision-making to improve procedural precision and long-term outcomes.

Against this clinical backdrop, device developers and healthcare systems are balancing several imperatives: improving acute procedural success, reducing repeat interventions, and demonstrating durable patient benefit that aligns with payor expectations. Advances in device design, such as refined atherectomy modalities for calcified plaque modification and enhanced drug-delivery balloon technologies to limit restenosis, are complemented by procedural shifts favoring minimally invasive access and shorter hospital stays. These dynamics necessitate cross-functional strategies that link clinical evidence generation, regulatory pathways, reimbursement positioning, and supply chain resilience.

This executive summary synthesizes current drivers affecting coronary devices and highlights structural shifts likely to influence product adoption, clinical practice, and commercial strategy. The analysis places clinical innovation in the context of health system priorities and operational realities, offering a structured foundation for executives and clinical leaders to align investments with evolving unmet needs.

How imaging, physiology, plaque modification, and procedural access trends are converging to redefine therapeutic benchmarks and device adoption in coronary care

Several transformative shifts are reshaping how coronary interventions are conceived, designed, and delivered, and these shifts are accelerating the convergence of imaging, physiology, and therapeutic device capabilities. First, intravascular imaging and physiologic assessment are moving from optional adjuncts to central components of case planning and optimization. The broader adoption of intravascular ultrasound and optical coherence tomography, alongside fractional flow reserve-guided decision-making, has increased lesion-level diagnostic precision and enabled more targeted device selection and deployment strategies.

Second, the growth in complex lesion subsets, particularly calcified coronary disease, has strengthened demand for specialized plaque-modification tools. Atherectomy technologies, including laser, orbital, and rotational modalities, are being refined to improve safety profiles and integration with adjunctive therapies. Concurrently, drug-eluting stent technologies and drug-coated balloons continue to evolve with refined polymer and drug formulations intended to extend durability while minimizing late adverse events. These converging device advancements are prompting hybrid procedural strategies where multiple complementary technologies are deployed within a single case.

Third, procedural access preferences are shifting toward radial approaches in many centers, reducing vascular complications and supporting faster patient throughput. This change is altering device design considerations related to profile, deliverability, and torque control. Finally, the digital and data-driven transformation in healthcare, including procedural analytics and real-world evidence generation, is enabling manufacturers to demonstrate value beyond immediate procedural success by documenting longitudinal outcomes, economic impact, and quality-of-life improvements. Collectively, these shifts are reconfiguring competitive dynamics and establishing new benchmarks for clinical evidence and device performance.

Assessing the cumulative operational, procurement, and regulatory consequences of United States tariff adjustments on coronary device supply chains and pricing strategies

The introduction of tariffs and trade policy changes in the United States in 2025 has exerted a cumulative influence across device sourcing, pricing strategies, and supply chain architecture, prompting industry actors to reassess operational models. Manufacturers with significant component or finished-goods exposure to affected jurisdictions experienced margin pressure, which in turn accelerated initiatives to diversify suppliers and examine nearshoring alternatives. These adaptations emphasized dual-sourcing strategies, qualification of alternative suppliers, and inventory optimization to sustain clinical supply continuity.

In parallel, procurement departments and health systems revisited contracting frameworks to account for potential cost volatility. Longer-term agreements and price-protection clauses have been negotiated to mitigate exposure, while some purchasers adopted more active inventory management and demand forecasting to reduce procurement friction. The tariffs also intensified focus on manufacturing footprint resilience, encouraging investment in regional manufacturing capacity and contract manufacturing partnerships in the Americas.

Regulatory and compliance burdens increased as well, since product relabeling, changes in country-of-origin documentation, and logistics re-routing added administrative complexity. Companies responded by strengthening cross-functional teams combining regulatory affairs, quality, and supply chain expertise to accelerate change controls and maintain regulatory compliance. Strategically, the cumulative impact of tariffs compelled many players to prioritize product designs and sourcing strategies that minimize tariff-exposed components, accelerate local qualification efforts, and use evidence of clinical effectiveness to defend pricing power within constrained reimbursement environments.

Insightful segmentation analysis linking device modalities, treatment pathways, access strategies, and care settings to adoption levers and product positioning

A nuanced segmentation lens reveals distinct opportunity zones and operational considerations across device type, treatment modality, procedural approach, and end-user setting. When devices are categorized by type, the analysis must account for atherectomy systems-which include laser, orbital, and rotational iterations-each optimized for different plaque morphologies and clinical scenarios. Balloon catheter technologies span cutting, drug-coated, and standard designs, with drug-coated balloons growing in relevance for in-stent restenosis and small-vessel disease. Guidewire variants such as polymer-jacketed, PTFE-coated, and untreated options continue to serve differentiated procedural roles depending on lesion complexity and deliverability needs. Intravascular imaging systems encompass fractional flow reserve platforms, intravascular ultrasound, and optical coherence tomography, each contributing unique diagnostic resolution that informs device selection and deployment technique. Stent platforms include bare metal constructs, bioresorbable scaffolds, and drug-eluting designs, with trade-offs in acute scaffolding, long-term vessel healing, and device longevity shaping clinician preference.

Examining treatment types reveals that coronary artery bypass grafting remains an essential option for specific anatomic and multivessel presentations, with off-pump and on-pump strategies retaining particular clinical rationales. Percutaneous coronary intervention continues to expand in scope through adjunctive technologies and procedural refinements, whether performed with balloon angioplasty alone or combined with stenting. The choice between surgical and percutaneous pathways is increasingly individualized through multidisciplinary heart team assessment and enhanced lesion-level diagnostics.

Approach selection between transfemoral and transradial access frames device design and procedural logistics, since radial-first practices prioritize low-profile, highly deliverable devices, while femoral access may accommodate bulkier adjunctive tools. End-user segmentation across ambulatory surgical centers, cardiac centers, and hospitals reflects varying procedural complexity, resource intensity, and reimbursement considerations, creating differentiated adoption pathways. Each segmentation axis requires tailored evidence generation, pricing strategies, and service models to optimize uptake across heterogeneous clinical settings.

Regional dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence regulatory pathways, adoption priorities, and localized commercialization strategies

Regional dynamics create differentiated demand drivers and operational imperatives across the Americas, Europe Middle East & Africa, and Asia-Pacific, shaping regulatory pathways, reimbursement landscapes, and clinical practice patterns. In the Americas, procedural innovation often intersects with consolidated payer systems and large hospital networks that emphasize real-world outcomes and cost-effectiveness; there is strong appetite for demonstrable improvements in procedural efficiency and reduction in repeat interventions. This context incentivizes manufacturers to invest in robust post-market evidence and provider education programs that translate device advantages into measurable clinical and economic value.

In Europe, the Middle East and Africa, heterogeneous regulatory and reimbursement frameworks necessitate localized market-entry strategies. Western European markets frequently require rigorous health technology assessments and country-specific clinical evidence, while emerging markets in the broader region may prioritize cost containment and scalable solutions that support expanding procedural capacity. Manufacturers navigating this geography must align pricing, clinical support, and regulatory submissions to the expectations of diverse national health systems.

The Asia-Pacific region presents a combination of high-volume procedural markets and rapidly advancing clinical capabilities, with several countries investing significantly in interventional cardiology infrastructure. Local manufacturing and partnerships are particularly influential here, as regional supply chain integration and regulatory alignment can accelerate adoption. Across all regions, demographic shifts toward aging populations and rising cardiovascular disease burden drive sustained clinical demand, but regional reimbursement, provider training, and health system priorities will determine the pace and nature of device uptake.

How product integration, clinical evidence, supply chain robustness, and commercialization expertise define competitive advantage among coronary device manufacturers

Competitive dynamics among companies active in coronary device development are defined by a blend of technology leadership, clinical evidence generation, manufacturing scale, and go-to-market sophistication. Leading firms prioritize integrated portfolios that pair therapeutic devices with diagnostic platforms, enabling bundled procedural solutions that support better case selection and optimization. Investment in clinical trials, registries, and post-market surveillance continues to be a differentiator, as health systems increasingly reward demonstrable long-term outcomes and economic value.

Strategic partnerships, licensing agreements, and selective acquisitions are common tools to access complementary technologies, expand geographic reach, or accelerate entry into emerging procedural niches. Supply chain resilience and regulatory agility are prominent operational priorities, with companies enhancing redundancy through contract manufacturing networks and regional production capacity. Talent investment in clinical affairs, evidence generation, and reimbursement expertise is equally important to translate device performance into adoption and favorable procurement outcomes.

Product differentiation increasingly centers on deliverability, lesion-specific performance, and adjunctive diagnostic compatibility. Companies that offer clinician training programs, procedural support, and robust data capture capabilities are better positioned to shorten adoption curves and build long-term clinical endorsement. As the competitive landscape matures, winners will be those who can integrate technical innovation with pragmatic commercialization models that reflect clinician workflows and payer expectations.

Practical strategic imperatives for leaders to align product innovation, supply chain resilience, and evidence-driven commercialization for sustainable growth

Industry leaders should prioritize a portfolio strategy that emphasizes clinically meaningful differentiation, regulatory foresight, and supply chain adaptability to capture sustained value. First, invest selectively in device improvements that address high-impact clinical gaps such as calcified lesions, small-vessel disease, and restenosis, while ensuring that design changes enhance deliverability for radial approaches. Coordinated clinical programs that generate both randomized evidence and real-world registry data will strengthen value propositions with clinicians and payers, supporting broader adoption and reimbursement alignment.

Second, build resilient sourcing architectures by qualifying multiple suppliers, exploring regional manufacturing partnerships, and embedding tariff-aware procurement clauses to mitigate policy-driven cost shocks. Cross-functional teams should own rapid change-control processes to accelerate supplier onboarding while maintaining regulatory compliance. Third, couple product launches with comprehensive clinician education and procedural training that integrate intravascular imaging and physiology tools, thereby shortening learning curves and improving procedural outcomes. Digital platforms that capture procedural metrics and patient outcomes can support iterative improvement and strengthen post-market evidence.

Finally, adopt flexible commercial models that align pricing with demonstrated outcomes and system-level value, including bundled agreements and outcome-linked contracts where appropriate. Collaboration with health systems to pilot integrated care pathways can surface operational efficiencies and provide reference cases for wider adoption. These actions, executed in parallel, will enhance resilience and create defensible differentiation in an increasingly outcome-driven environment.

A rigorous, multi-modal research methodology integrating clinical evidence, stakeholder interviews, regulatory insights, and supply chain analysis to ensure robust conclusions

This analysis synthesizes insights drawn from a multi-modal research approach designed to reflect clinical practice, regulatory context, and supply chain realities. The methodology combined a comprehensive review of peer-reviewed clinical literature, procedural registries, and device labeling to establish device performance characteristics and clinical application patterns. In addition, structured interviews were conducted with interventional cardiologists, hospital procurement leaders, regulatory specialists, and device development executives to capture frontline perspectives on adoption drivers, unmet needs, and operational constraints.

Supplementary sources included a review of regulatory filings, standards guidance, and published health technology assessments to understand evidence expectations across jurisdictions. Supply chain analysis incorporated import-export data trends, published policy updates related to trade and tariffs, and anonymized insights from contract manufacturers to map procurement and manufacturing risk. Patent landscaping and pipeline tracking were used to identify emerging technologies and R&D focus areas.

Throughout the research process, findings were triangulated across sources to ensure robustness and to minimize single-source bias. Evidence synthesis emphasized clinical relevance, regulatory plausibility, and commercial applicability, providing a balanced foundation for the insights and recommendations presented herein.

A concise synthesis of clinical, operational, and strategic drivers that will determine which device strategies deliver enduring clinical and commercial value

The trajectory of coronary artery disease treatment devices is defined by technological refinement, procedural evolution, and an environment that rewards demonstrable clinical and economic value. Advances in intravascular imaging and physiology are enabling more precise, lesion-level decision-making, while targeted therapeutic devices-ranging from advanced atherectomy systems to drug-delivery balloons and modern stent platforms-are addressing increasingly complex clinical presentations. These clinical drivers intersect with operational realities such as access trends, payer scrutiny, and supply chain pressures, creating a landscape that favors integrated solutions and evidence-rich commercialization strategies.

Organizations that align device design with clinician workflow, invest in outcome-focused evidence generation, and build supply chain resilience will be best positioned to capture durable adoption. Regulatory agility and region-specific market approaches remain essential as jurisdictions vary in evidence requirements and reimbursement dynamics. Ultimately, sustained success will hinge on the ability to translate technical performance into clear clinical benefit and system-level value, enabling providers and payers to justify adoption amid competing budgetary and operational priorities.

The recommendations in this summary provide a roadmap for aligning R&D, regulatory, supply chain, and commercial actions to meet evolving clinician expectations and health system demands. Executives and clinical leaders can leverage these insights to prioritize investments that yield meaningful improvements in patient care and organizational outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Coronary Artery Disease Treatment Devices Market, by Device Type

  • 8.1. Atherectomy Device
    • 8.1.1. Laser Atherectomy
    • 8.1.2. Orbital Atherectomy
    • 8.1.3. Rotational Atherectomy
  • 8.2. Balloon Catheter
    • 8.2.1. Cutting Balloon Catheter
    • 8.2.2. Drug-Coated Balloon Catheter
    • 8.2.3. Standard Balloon Catheter
  • 8.3. Guidewire
    • 8.3.1. Polymer-Jacketed
    • 8.3.2. PTFE-Coated
    • 8.3.3. Untreated
  • 8.4. Intravascular Imaging System
    • 8.4.1. Fractional Flow Reserve
    • 8.4.2. Intravascular Ultrasound
    • 8.4.3. Optical Coherence Tomography
  • 8.5. Stent
    • 8.5.1. Bare Metal Stent
    • 8.5.2. Bioresorbable Scaffold
    • 8.5.3. Drug Eluting Stent

9. Coronary Artery Disease Treatment Devices Market, by Treatment Type

  • 9.1. Coronary Artery Bypass Grafting
    • 9.1.1. Off Pump
    • 9.1.2. On Pump
  • 9.2. Percutaneous Coronary Intervention
    • 9.2.1. With Balloon Angioplasty
    • 9.2.2. With Stenting

10. Coronary Artery Disease Treatment Devices Market, by Approach

  • 10.1. Transfemoral Approach
  • 10.2. Transradial Approach

11. Coronary Artery Disease Treatment Devices Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Cardiac Centers
  • 11.3. Hospitals

12. Coronary Artery Disease Treatment Devices Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Coronary Artery Disease Treatment Devices Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Coronary Artery Disease Treatment Devices Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Coronary Artery Disease Treatment Devices Market

16. China Coronary Artery Disease Treatment Devices Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. B. Braun Melsungen AG
  • 17.7. Biotronik SE & Co. KG
  • 17.8. Boston Scientific Corporation
  • 17.9. Cardinal Health, Inc.
  • 17.10. Cook Medical Inc.
  • 17.11. Edwards Lifesciences Corporation
  • 17.12. GE Healthcare (subsidiary of General Electric Company)
  • 17.13. Johnson & Johnson
  • 17.14. Koninklijke Philips N.V.
  • 17.15. Lepu Medical Technology (Beijing) Co., Ltd.
  • 17.16. Medtronic plc
  • 17.17. Meril Life Sciences Pvt. Ltd.
  • 17.18. Merit Medical Systems, Inc.
  • 17.19. MicroPort Scientific Corporation
  • 17.20. OrbusNeich Medical Company Limited
  • 17.21. Shockwave Medical, Inc.
  • 17.22. Terumo Corporation
  • 17.23. W. L. Gore & Associates, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY APPROACH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ATHERECTOMY DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ATHERECTOMY DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ATHERECTOMY DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ATHERECTOMY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY LASER ATHERECTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY LASER ATHERECTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY LASER ATHERECTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ORBITAL ATHERECTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ORBITAL ATHERECTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ORBITAL ATHERECTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ROTATIONAL ATHERECTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ROTATIONAL ATHERECTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ROTATIONAL ATHERECTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BALLOON CATHETER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BALLOON CATHETER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BALLOON CATHETER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BALLOON CATHETER, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CUTTING BALLOON CATHETER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CUTTING BALLOON CATHETER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CUTTING BALLOON CATHETER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DRUG-COATED BALLOON CATHETER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DRUG-COATED BALLOON CATHETER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DRUG-COATED BALLOON CATHETER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STANDARD BALLOON CATHETER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STANDARD BALLOON CATHETER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STANDARD BALLOON CATHETER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY GUIDEWIRE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY GUIDEWIRE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY GUIDEWIRE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY GUIDEWIRE, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY POLYMER-JACKETED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY POLYMER-JACKETED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY POLYMER-JACKETED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY PTFE-COATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY PTFE-COATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY PTFE-COATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY UNTREATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY UNTREATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY UNTREATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR IMAGING SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR IMAGING SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR IMAGING SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR IMAGING SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY FRACTIONAL FLOW RESERVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY FRACTIONAL FLOW RESERVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY FRACTIONAL FLOW RESERVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY OPTICAL COHERENCE TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY OPTICAL COHERENCE TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY OPTICAL COHERENCE TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STENT, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BARE METAL STENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BARE METAL STENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BARE METAL STENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BIORESORBABLE SCAFFOLD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BIORESORBABLE SCAFFOLD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BIORESORBABLE SCAFFOLD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DRUG ELUTING STENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DRUG ELUTING STENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DRUG ELUTING STENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY OFF PUMP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY OFF PUMP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY OFF PUMP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ON PUMP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ON PUMP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ON PUMP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY WITH BALLOON ANGIOPLASTY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY WITH BALLOON ANGIOPLASTY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY WITH BALLOON ANGIOPLASTY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY WITH STENTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY WITH STENTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY WITH STENTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TRANSFEMORAL APPROACH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TRANSFEMORAL APPROACH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TRANSFEMORAL APPROACH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TRANSRADIAL APPROACH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TRANSRADIAL APPROACH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TRANSRADIAL APPROACH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CARDIAC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CARDIAC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CARDIAC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ATHERECTOMY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BALLOON CATHETER, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY GUIDEWIRE, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR IMAGING SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STENT, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ATHERECTOMY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BALLOON CATHETER, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY GUIDEWIRE, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR IMAGING SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STENT, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ATHERECTOMY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BALLOON CATHETER, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY GUIDEWIRE, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR IMAGING SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STENT, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ATHERECTOMY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BALLOON CATHETER, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY GUIDEWIRE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR IMAGING SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STENT, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ATHERECTOMY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BALLOON CATHETER, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY GUIDEWIRE, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR IMAGING SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STENT, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ATHERECTOMY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BALLOON CATHETER, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY GUIDEWIRE, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR IMAGING SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STENT, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ATHERECTOMY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BALLOON CATHETER, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY GUIDEWIRE, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR IMAGING SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STENT, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ATHERECTOMY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BALLOON CATHETER, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY GUIDEWIRE, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR IMAGING SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STENT, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ATHERECTOMY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BALLOON CATHETER, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY GUIDEWIRE, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR IMAGING SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STENT, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. GCC CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. GCC CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. GCC CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ATHERECTOMY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 219. GCC CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BALLOON CATHETER, 2018-2032 (USD MILLION)
  • TABLE 220. GCC CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY GUIDEWIRE, 2018-2032 (USD MILLION)
  • TABLE 221. GCC CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR IMAGING SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 222. GCC CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STENT, 2018-2032 (USD MILLION)
  • TABLE 223. GCC CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. GCC CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, 2018-2032 (USD MILLION)
  • TABLE 225. GCC CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 226. GCC CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 227. GCC CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ATHERECTOMY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BALLOON CATHETER, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY GUIDEWIRE, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR IMAGING SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STENT, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ATHERECTOMY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BALLOON CATHETER, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY GUIDEWIRE, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR IMAGING SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STENT, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. G7 CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. G7 CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. G7 CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY ATHERECTOMY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 255. G7 CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY BALLOON CATHETER, 2018-2032 (USD MILLION)
  • TABLE 256. G7 CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY GUIDEWIRE, 2018-2032 (USD MILLION)
  • TABLE 257. G7 CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY INTRAVASCULAR IMAGING SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 258. G7 CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY STENT, 2018-2032 (USD MILLION)
  • TABLE 259. G7 CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. G7 CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, 2018-2032 (USD MILLION)
  • TABLE 261. G7 CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY PERCUTANEOUS CORONARY INTERVENTION, 2018-2032 (USD MILLION)
  • TABLE 262. G7 CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY APPROACH, 2018-2032 (USD MILLION)
  • TABLE 263. G7 CORONARY ARTERY DISEASE TREATMENT DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 264. NATO CORONARY ARTERY DISEAS